Physician profile
Gregory J Warth
NPI 1730114471
$685.62
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.47 · 2020: $25.39 · 2021: $328 · 2022: $71.74 · 2023: $214 · 2024: $33.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $124.93 | 2021 | |
| Esperion Therapeutics, INC. | $89.65 | 2021 | |
| Novo Nordisk INC | $72.16 | 2021-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $54.10 | 2019-2023 | |
| Lilly USA, LLC | $49.45 | 2022-2024 | Mounjaro, Zepbound |
| Amgen INC. | $47.74 | 2021-2023 | Otezla, Repatha |
| Amarin Pharma, INC. | $47.50 | 2021 | |
| Sumitomo Pharma America, INC. | $42.88 | 2023 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $37.21 | 2020-2021 | |
| Abbvie INC. | $33.06 | 2023 | Vraylar, Ubrelvy, Qulipta |
| Collegium Pharmaceutical, INC. | $23.86 | 2022 | |
| Biogen, INC. | $20.80 | 2021 | |
| Glaxosmithkline, LLC. | $15.51 | 2023 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $13.63 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.14 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Warth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.